摘要
miRNAs是非编码RNA分子,它们的反常调节可能导致癌症的发生。但是,miRNA功能紊乱是怎样导致弥漫性大B细胞淋巴瘤(DLBCL)的机制还没有很好的确认。在这项研究中,我们分析了在4个DLBCL细胞株和168个病人样本中miR-224的表达,我们发现miR-224的表达在DLBCL细胞株中与正常B细胞比较是下调的,但是在生发中心B细胞样和活化B细胞样之间在统计学上没有差异。利用生物信息学预测与荧光素酶报告化验分析,我们揭示了miR-224通过结合到CD59的3’端非翻译区的方式直接下调CD59表达。我们也使用免疫组化染色方式染色人DLBCL样本细胞的CD59,并分析miR-224,CD59的表达和分别使用利妥昔单抗,环磷酰胺,阿霉素,长春新碱和泼尼松(R-CHOP)治疗的DLBCL病人的总的/复发生存率的相关性。我们发现miR-224可能导致DLBCL的发生,更重要的是miR-224和CD59的表达能够预测R-CHOP治疗DLBCL病人后的反应和效果。
关键词: CD59,致弥漫性大B细胞淋巴瘤 (DLBCL),小分子RNA,miR-224, R-CHOP.
图形摘要
Current Cancer Drug Targets
Title:Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Volume: 14 Issue: 7
Author(s): Guoqi Song, Guorong Song, Huiyun Ni, Ling Gu, Hong Liu, Baoan Chen, Bangshun He, Yuqin Pan, Shukui Wang and William C. Cho
Affiliation:
关键词: CD59,致弥漫性大B细胞淋巴瘤 (DLBCL),小分子RNA,miR-224, R-CHOP.
摘要: miRNAs are non-coding RNA molecules; their deregulations may contribute to cancer pathogenesis. However, the mechanisms of how miRNA dysfunction contributes to the lymphomagenesis of diffuse large B-cell lymphoma (DLBCL) are not well established. In this study, we analyzed the expression of miR-224 in four DLBCL cell lines and 168 patients’ specimens. We found that the expression of miR-224 in DLBCL was down-regulated compared with normal B-cell but was not statistically different between the germinal center B-cell-like-type and the activated B-cell-like-type. Using bioinformatics prediction and luciferase report assays, we demonstrated that miR-224 directly down-regulated CD59 expression by binding to its 3’-untranslated region. We also used immunohistochemical staining of CD59 in human DLBCL specimens and analyzed the relationship between the expression of miR-224, CD59 and the overall/progress-free survival of DLBCL patients who were uniformly treated with rituximab,cyclophosphamide, adriamycin, vincristine, and prednisone (R-CHOP). We found that miR-224 may contribute to DLBCL pathogenesis. Most importantly, the expression of miR-224 and CD59 can predict the response and outcome of DLBCL patients treated with R-CHOP.
Export Options
About this article
Cite this article as:
Song Guoqi, Song Guorong, Ni Huiyun, Gu Ling, Liu Hong, Chen Baoan, He Bangshun, Pan Yuqin, Wang Shukui and Cho C. William, Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP, Current Cancer Drug Targets 2014; 14 (7) . https://dx.doi.org/10.2174/1568009614666140818211103
DOI https://dx.doi.org/10.2174/1568009614666140818211103 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma
Current Pharmaceutical Design Polyethylenimine-based Formulations for Delivery of Oligonucleotides
Current Medicinal Chemistry Biodistribution Processes as Underestimated Confounders in Translational Stroke Research
Current Medicinal Chemistry Mechanisms and Immunological Roles of Apoptosis in Molluscs
Current Pharmaceutical Design Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Oncogenic Fusion Tyrosine Kinases as Molecular Targets for Anti-Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Omalizumab: Not Only For Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Benzimidazole Heterocycle as a Privileged Scaffold in Antiviral Agents
Mini-Reviews in Organic Chemistry Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity
Current Medicinal Chemistry Yttrium-90 – Current Status, Expected Availability and Applications of a High Beta Energy Emitter
Current Radiopharmaceuticals Apoptosis in Anthracycline Cardiomyopathy
Current Pediatric Reviews MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Imaging of Tumor Angiogenesis: Current Approaches and Future Prospects
Current Pharmaceutical Design Structure-Based Rationale for Interleukin 5 Receptor Antagonism
Current Pharmaceutical Design Antisense Oligonucleotides as a Powerful Molecular Strategy for Gene Therapy in Cardiovascular Diseases
Current Pharmaceutical Design NQDI 1, An Inhibitor of ASK1 Attenuates Acute Ischemic Renal Injury by Modulating Oxidative Stress and Cell Death
Cardiovascular & Hematological Agents in Medicinal Chemistry Specific Biologic Therapy with Tumor Necrosis Factor Inhibitors in Patients with Inflammatory Myopathy
Current Rheumatology Reviews